Hovione and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions
Commitment to partnership and joint innovation for cell and gene therapies
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Commitment to partnership and joint innovation for cell and gene therapies
Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®
Hovione today announced an extension of collaboration on Zerion’s Dispersome® technology into the nutraceutical/dietary supplements field.
Outsourced Pharma, April 2023
Hovione is Growing
Hovione commitment to setting SBTs in line with the Paris Agreement
Effective May 1st, 2020
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction